Treatment
Olaparib clinical trials
We’re tracking 77 recruiting studies that include Olaparib, each written for real people, not researchers, below.
Recruiting studies
- NCT05568550RecruitingPhase 2
Radiation with or without olaparib for high-risk prostate cancer
This Phase 2 study tests whether adding a medicine called olaparib to radiation helps men with high-risk prostate cancer. You may receive radiation alone or radiation plus olaparib, and the study looks at whether the combination works better.
Lexington, KentuckyAges 18 years+ - NCT05188508RecruitingPhase 2
Pembrolizumab, olaparib, and temozolomide for recurrent glioma
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
Hartford, ConnecticutAges 18 years+ - NCT05093231RecruitingPhase 2
Pembrolizumab plus olaparib for stage 4 pancreatic cancer
This trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a DNA-repair drug) can work better for people with metastatic (stage 4) pancreatic cancer. It targets tumors with certain lab marker results and aims to improve control of cancer growth.
MelbourneAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Anchorage, AlaskaAges 18 years+ - NCT04633239RecruitingPhase 1
Testing abemaciclib plus olaparib for recurrent ovarian cancer
This Phase 1 trial studies whether adding abemaciclib to olaparib can treat women with recurrent platinum-resistant ovarian cancer. It aims to find a safe dose and see how well the combination can control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04683679RecruitingPhase 2
Radiation plus pembrolizumab and olaparib for certain breast cancers
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
Basking Ridge, New JerseyAges 18 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04038502RecruitingPhase 2
Comparing carboplatin and olaparib for prostate cancer with BRCA gene changes
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
West Los Angeles, CaliforniaAges 18 years+ - NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+ - NCT06525298RecruitingPhase 1/Phase 2
Study of EIS-12656 for solid tumors with DNA repair defects
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Houston, TexasAges 18 years+ - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Grand Rapids, MichiganAges 18 years+ - NCT06437353RecruitingPhase 2
Surufatinib combo for first-line and maintenance in high-risk ovarian cancer
This trial tests a combination of drugs (Surufatinib with carboplatin/paclitaxel) as first treatment for high-risk ovarian cancer, followed by a different combination (Surufatinib with olaparib) to keep the cancer from coming back. It aims to see if these targeted therapies work better than the standard approach.
Hefei, AnhuiAges 18–75 - NCT06739395RecruitingPhase 2
Precision cancer trial for patients out of standard options
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06686745RecruitingPhase 1
Study of an experimental drug alone and with combination for advanced solid tumors
This trial tests a new drug called SIM0508, given alone or with another drug (olaparib), in people with advanced ovarian, prostate, breast, or pancreatic cancer. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07460180RecruitingPhase 1/Phase 2
PARP inhibitor with chemo and HIPEC for ovarian cancer
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
AmsterdamAges 18–100 - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05536128RecruitingPhase 2
Fulvestrant plus DNA damage drugs after CDK4/6 treatment failure
This Phase 2 trial studies whether combining fulvestrant with medicines that block DNA repair can help treat HR+/HER2- metastatic or inoperable breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor. It also aims to check the safety of this combination and see if it can control the cancer for longer.
SeoulAges 19 years+ - NCT05432518RecruitingEarly Phase 1
Pilot study for surgery and new medicine in recurrent glioblastoma
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
Calgary, AlbertaAges 18 years+ - NCT07151911Recruiting
Study of drugs for high-risk early breast cancer
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
Modena, ModenaAges 18 years+
Common questions
- Are there clinical trials studying Olaparib?
- Yes. Clin2 currently lists 77 recruiting studies that include Olaparib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Olaparib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Olaparib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Olaparib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.